TLRs and interferons: A central paradigm in autoimmunity

Current Opinion in Immunology

Volumn 25, Issue 6, 2013, Pages 720-727

  Kono, Dwight H ^a   Baccala, Roberto ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGS 009; ALPHA INTERFERON; ANIFROLUMAB; AUTOANTIBODY; DV 1179; DYNAVAX; IMMUNOSUPPRESSIVE AGENT; IMO 8400; INTERFERON; NUCLEIC ACID; RONTALIZUMAB; SIFALIMUMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; CELL NUCLEUS; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; LUPUS VULGARIS; NONHUMAN; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INTERFERON TYPE I; NUCLEIC ACIDS; TOLL-LIKE RECEPTORS;

EID: 84889080474     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.10.006     Document Type: Review

References (81)

1. Ronnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013, 25:248-253.
2. Ronnblom L., Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:F59-F63.
3. Di Domizio J., Cao W. Fueling autoimmunity: type I interferon in autoimmune diseases. Expert Rev Clin Immunol 2013, 9:201-210.
4. Elkon K.B., Wiedeman A. Type I, IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 2012, 24:499-505.
5. Santiago-Raber M., Baccala R., Haraldsson M.K., Choubey D., Stewart T.A., Kono D.H., Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
6. Baccala R., Gonzalez-Quintial R., Schreiber R.D., Lawson B.R., Kono D.H., Theofilopoulos A.N. Anti-IFN-alpha/beta receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol 2012, 189:5976-5984.
7. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142.
8. Braun D., Geraldes P., Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003, 20:15-25.
9. Gough D.J., Messina N.L., Clarke C.J., Johnstone R.W., Levy D.E. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012, 36:166-174.
10. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
11. Baccala R., Gonzalez-Quintial R., Blasius A.L., Rimann I., Ozato K., Kono D.H., Beutler B., Theofilopoulos A.N. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc Natl Acad Sci U S A 2013, 110:2940-2945.
12. Gall A., Treuting P., Elkon K.B., Loo Y.M., Gale M., Barber G.N., Stetson D.B. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36:120-131.
13. Yoshida H., Okabe Y., Kawane K., Fukuyama H., Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol 2005, 6:49-56.
14. Crow Y.J. Type I. interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011, 1238:91-98.
15. Lee P.Y., Weinstein J.S., Nacionales D.C., Scumpia P.O., Li Y., Butfiloski E., van Rooijen N., Moldawer L., Satoh M., Reeves W.H. A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008, 180:5101-5108.
16. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
17. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692.
18. Wu J., Sun L., Chen X., Du F., Shi H., Chen C., Chen Z.J. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339:826-830.
19. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
20. O'Neill L.A. Immunology. Sensing the dark side of DNA. Science 2013, 339:763-764.
21. Atianand M.K., Fitzgerald K.A. Molecular basis of DNA recognition in the immune system. J Immunol 2013, 190:1911-1918.
22. Cavlar T., Ablasser A., Hornung V. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunol Cell Biol 2012, 90:474-482.
23. Theofilopoulos A.N., Kono D.H., Beutler B., Baccala R. Intracellular nucleic acid sensors and autoimmunity. J Interferon Cytokine Res 2011, 31:867-886.
24. Yanai H., Ban T., Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 2012, 33:633-640.
25. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
26. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
27. Knight J.S., Kaplan M.J. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr Opin Rheumatol 2012, 24:441-450.
28. Campbell A.M., Kashgarian M., Shlomchik M.J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med 2012, 4:157ra141.
29. Bronson P.G., Chaivorapol C., Ortmann W., Behrens T.W., Graham R.R. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012, 24:530-537.
30. Robinson T., Kariuki S.N., Franek B.S., Kumabe M., Kumar A.A., Badaracco M., Mikolaitis R.A., Guerrero G., Utset T.O., Drevlow B.E., et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J Immunol 2011, 187:1298-1303.
31. Briggs T.A., Rice G.I., Daly S., Urquhart J., Gornall H., Bader-Meunier B., Baskar K., Baskar S., Baudouin V., Beresford M.W., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 2011, 43:127-131.
32. Yang Y.G., Lindahl T., Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007, 131:873-886.
33. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
34. Rice G.I., Kasher P.R., Forte G.M., Mannion N.M., Greenwood S.M., Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A., et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet 2012, 44:1243-1248.
35. Cham C.M., Ko K., Niewold T.B. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:780436.
36. Lood C., Gullstrand B., Truedsson L., Olin A.I., Alm G.V., Ronnblom L., Sturfelt G., Eloranta M.L., Bengtsson A.A. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009, 60:3081-3090.
37. Santer D.M., Hall B.E., George T.C., Tangsombatvisit S., Liu C.L., Arkwright P.D., Elkon K.B. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol 2010, 185:4738-4749.
38. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
39. Moisini I., Huang W., Bethunaickan R., Sahu R., Ricketts P.G., Akerman M., Marion T., Lesser M., Davidson A. The Yaa locus and IFN-alpha fine-tune germinal center B cell selection in murine systemic lupus erythematosus. J Immunol 2012, 189:4305-4312.
40. Green N.M., Laws A., Kiefer K., Busconi L., Kim Y.M., Brinkmann M.M., Trail E.H., Yasuda K., Christensen S.R., Shlomchik M.J., et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol 2009, 183:1569-1576.
41. Theofilopoulos A.N., Gonzalez-Quintial R., Lawson B.R., Koh Y.T., Stern M.E., Kono D.H., Beutler B., Baccala R. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol 2010, 6:146-156.
42. Marshak-Rothstein A., Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007, 25:419-441.
43. Shlomchik M.J. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 2009, 21:626-633.
44. Koh Y.T., Scatizzi J.C., Gahan J.D., Lawson B.R., Baccala R., Pollard K.M., Beutler B.A., Theofilopoulos A.N., Kono D.H. Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells. J Immunol 2013, 190:4982-4990.
45. Haas T., Metzger J., Schmitz F., Heit A., Muller T., Latz E., Wagner H. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008, 28:315-323.
46. Gronwall C., Chen Y., Vas J., Khanna S., Thiel S., Corr M., Kono D.H., Silverman G.J. MAPK phosphatase-1 is required for regulatory natural autoantibody-mediated inhibition of TLR responses. Proc Natl Acad Sci U S A 2012, 109:19745-19750.
47. Peng Y., Martin D.A., Kenkel J., Zhang K., Ogden C.A., Elkon K.B. Innate and adaptive immune response to apoptotic cells. J Autoimmun 2007, 29:303-309.
48. Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003, 171:3296-3302.
49. Avalos A.M., Uccellini M.B., Lenert P., Viglianti G.A., Marshak-Rothstein A. FcgammaRIIB regulation of BCR/TLR-dependent autoreactive B-cell responses. Eur J Immunol 2010, 40:2692-2698.
50. Nickerson K.M., Christensen S.R., Cullen J.L., Meng W., Luning Prak E.T., Shlomchik M.J. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013, 190:1447-1456.
51. Teichmann L.L., Schenten D., Medzhitov R., Kashgarian M., Shlomchik M.J. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 2013, 38:528-540.
52. Walsh E.R., Pisitkun P., Voynova E., Deane J.A., Scott B.L., Caspi R.R., Bolland S. Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc Natl Acad Sci U S A 2012, 109:16276-16281.
53. Kono D.H., Haraldsson M.K., Lawson B.R., Pollard K.M., Koh Y.T., Du X., Arnold C.N., Baccala R., Silverman G.J., Beutler B.A., et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A 2009, 106:12061-12066.
54. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
55. Nickerson K.M., Christensen S.R., Shupe J., Kashgarian M., Kim D., Elkon K., Shlomchik M.J. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010, 184:1840-1848.
56. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331.
57. Sadanaga A., Nakashima H., Akahoshi M., Masutani K., Miyake K., Igawa T., Sugiyama N., Niiro H., Harada M. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007, 56:1618-1628.
58. Cervantes J.L., Weinerman B., Basole C., Salazar J.C. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012, 9:434-438.
59. Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004, 50:1861-1872.
60. Sasai M., Iwasaki A. Love triangle between Unc93B1, TLR7, and TLR9 prevents fatal attraction. Immunity 2011, 35:3-5.
61. Demaria O., Pagni P.P., Traub S., de Gassart A., Branzk N., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Flavell R.A., Alexopoulou L. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 2010, 120:3651-3662.
62. Yoshinobu K., Baudino L., Santiago-Raber M.L., Morito N., Dunand-Sauthier I., Morley B.J., Evans L.H., Izui S. Selective up-regulation of intact, but not defective env RNAs of endogenous modified polytropic retrovirus by the Sgp3 locus of lupus-prone mice. J Immunol 2009, 182:8094-8103.
63. Baudino L., Yoshinobu K., Morito N., Santiago-Raber M.L., Izui S. Role of endogenous retroviruses in murine SLE. Autoimmun Rev 2010, 10:27-34.
64. Teichmann L.L., Ols M.L., Kashgarian M., Reizis B., Kaplan D.H., Shlomchik M.J. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33:967-978.
65. Kawane K., Ohtani M., Miwa K., Kizawa T., Kanbara Y., Yoshioka Y., Yoshikawa H., Nagata S. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002.
66. Ahn J., Gutman D., Saijo S., Barber G.N. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 2012, 109:19386-19391.
67. Ramantani G., Kohlhase J., Hertzberg C., Innes A.M., Engel K., Hunger S., Borozdin W., Mah J.K., Ungerath K., Walkenhorst H., et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum 2010, 62:1469-1477.
68. Rice G., Patrick T., Parmar R., Taylor C.F., Aeby A., Aicardi J., Artuch R., Montalto S.A., Bacino C.A., Barroso B., et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007, 81:713-725.
69. Hedrich C.M., Fiebig B., Hauck F.H., Sallmann S., Hahn G., Pfeiffer C., Heubner G., Lee-Kirsch M.A., Gahr M. Chilblain lupus erythematosus-a review of literature. Clin Rheumatol 2008, 27:1341.
70. Pothlichet J., Niewold T.B., Vitour D., Solhonne B., Crow M.K., Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 2011, 3:142-152.
71. Molineros J.E., Maiti A.K., Sun C., Looger L.L., Han S., Kim-Howard X., Glenn S., Adler A., Kelly J.A., Niewold T.B., et al. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 2013, 9:e1003222.
72. Gateva V., Sandling J.K., Hom G., Taylor K.E., Chung S.A., Sun X., Ortmann W., Kosoy R., Ferreira R.C., Nordmark G., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233.
73. Crampton S.P., Deane J.A., Feigenbaum L., Bolland S. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J Immunol 2012, 188:1451-1459.
74. Petri M., Wallace D.J., Spindler A., Chindalore V., Kalunian K., Mysler E., Neuwelt C.M., Robbie G., White W.I., Higgs B.W., et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013, 65:1011-1021.
75. McBride J.M., Jiang J., Abbas A.R., Morimoto A., Li J., Maciuca R., Townsend M., Wallace D.J., Kennedy W.P., Drappa J. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012, 64:3666-3676.
76. Zagury D., Le Buanec H., Mathian A., Larcier P., Burnett R., Amoura Z., Emilie D., Peltre G., Bensussan A., Bizzini B., et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A 2009, 106:5294-5299.
77. Wang B., Higgs B.W., Chang L., Vainshtein I., Liu Z., Streicher K., Liang M., White W.I., Yoo S., Richman L., et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther 2013, 93:483-492.
78. Guiducci C., Tripodo C., Gong M., Sangaletti S., Colombo M.P., Coffman R.L., Barrat F.J. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010, 207:2931-2942.
79. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586.
80. Zhu F., Jiang W., Dong Y., Kandimalla E., La Monica N., Agrawal S. IMO-8400, a novel TLR7, TLR8, and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice (abstract). J Immunol 2012, 188:119.112.
81. Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., Chan J.H., Wright T., Punaro M., Bolland S., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465:937-941.